ClinicalTrials.gg
CompletedNCT01245751Updated Apr 12, 2017Results posted

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

A Phase 3 interventional study of Zoster Vaccine, Live in Herpes Zoster and Varicella-zoster Vaccine, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
6th of 29
600 · median 160
Started
2011
with 3 others
Phase 3
9 of 29
none open now
Registered
11th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 6th largest by enrollment, is one of 4 that started in 2011, is one of 9 in phase 3, and was the 11th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose. This information was compared to similar information obtained after Zoster Vaccine, Live administration to age-matched and younger participants who received their first dose of Zoster Vaccine, Live. The study was designed to determine: 1) whether a booster dose of Zoster Vaccine, Live in participants ≥70 years of age induces an antibody response that is noninferior to that of a first dose of Zoster Vaccine, Live in participants matched for age; 2) whether a booster dose of Zoster Vaccine, Live induces an acceptable rise in the level of varicella-zoster virus (VZV) antibodies.

Read the detailed description

All participants were followed for one year after completion of the 42-day post-vaccination period while Groups 1 and 2 were followed for a total of three years.

03

Conditions studied

  • Herpes Zoster
  • Varicella-zoster Vaccine

Browse trials for

Keywords

  • Shingles
  • Vaccine
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Groups:

    • Must not have a fever of ≥100.4° F on the day of vaccination
    • Any underlying chronic illness must be in stable condition
    • History of varicella or residence in a VZV-endemic area for ≥30 years
  • Group 1:

    • 70 years of age or older
    • Took part in the Shingles Prevention Study (SPS) (V211-004, NCT00007501) and received a single dose of Zoster Vaccine, Live ≥10 years prior to enrollment in this study
  • Group 2:

    • 70 years of age or older
  • Group 3:

    • 60 to 69 years of age
  • Group 4:

    • 50 to 59 years of age

Exclusion criteria

Exclusion Criteria:

  • All Groups:

    • History of reaction to any vaccine component or an anaphylactic/anaphylactoid reaction to neomycin
    • Prior history of herpes zoster
    • Pregnant or breast-feeding, or expecting to conceive within the duration of the study
    • Has been treated with immunoglobulin or any blood products, other than autologous (self-donated) blood transfusion, in the 5 months prior to vaccination
    • Received any other vaccine within 4 weeks prevaccination
    • On therapy
    • Has known or suspected immune dysfunction
    • Is taking any non-topical antiviral therapy with activity against herpesviruses, including, but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir.
  • Groups 2, 3, and 4:

    • Has previously received any varicella or zoster vaccine
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Group 1: Booster Dose Participants ≥70 years of age

    Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)

    Biological: Zoster Vaccine, Live

  • Experimental
    Group 2: First Dose Participants ≥70 years of age

    Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age

    Biological: Zoster Vaccine, Live

  • Experimental
    Group 3: First Dose Participants ≥60 and <70 years of age

    Herpes zoster history-negative participants ≥60 and \<70 years of age who have never received Zoster Vaccine, Live

    Biological: Zoster Vaccine, Live

  • Experimental
    Group 4: First Dose Participants ≥50 and <60 years of age

    Herpes zoster history-negative participants ≥50 and \<60 years of age who have never received Zoster Vaccine, Live

    Biological: Zoster Vaccine, Live

Interventions

  • Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study

    Also known as: V211, ZOSTAVAX™

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)

    VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)

    Time frame: Day 1 (Baseline) and Week 6 postvaccination

  2. Geometric Mean Fold Rise (GMFR) From Day 1 (Baseline) to Week 6 Postvaccination in VZV Antibody Titers

    VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.

    Time frame: Day 1 (Baseline) and Week 6 postvaccination

Secondary outcomes

  1. Number of Participants Reporting One or More Adverse Experiences

    An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience. A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention. Vaccine-related AEs were those assessed by the investigator as definitely, probably, or possibly related to vaccine administration. This outcome measure applies only to AEs collected after vaccination in Part 1 of the current study.

    Time frame: Up to 42 days postvaccination

07

Results

Posted May 29, 2013

Participant flow

Part 1: Day 1 to Week 52 (1 Year)
Participant flow — Part 1: Day 1 to Week 52 (1 Year)
MilestoneGroup 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of Age
Started201199100100
Completed 42-day postvaccination period201199100100
Completed19919410098
Not completed2502
Withdrew: Death2100
Withdrew: Lost to follow-up0002
Withdrew: Withdrawal by subject0400
Part 2: Week 156 (3 Year) Visit
Participant flow — Part 2: Week 156 (3 Year) Visit
MilestoneGroup 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of Age
Started16113900
Completed16113900
Not completed0000

Outcome measures

PrimaryGeometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)

VZV antibody titers were determined by glycoprotein enzyme-linked immunosorbent assay (gpELISA)

Time frame:
Day 1 (Baseline) and Week 6 postvaccination
Reported as:
Geometric mean · gpELISA Units/mL
Geometric Mean Titer (GMT) of the Antibody Responses to Varicella-Zoster Virus (VZV)
gpELISA Units/mLGroup 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of Age
Day 1 (Baseline), n=201, 199248.0 (219.7 to 280.0)254.2 (223.5 to 289.3)
Week 6 postvaccination, n=198, 195389.1 (351.4 to 430.8)368.6 (330.5 to 411.6)
Statistical analysis
  • Group 1: Booster Dose Participants ≥70 Years of Age vs Group 2: First Dose Participants ≥70 Years of Age · Longitudinal regression model · p = <0.001 (The alpha threshold for statistical significance is 0.025 (1-sided)) · Gmt ratio: 1.05 · 95% CI 0.97 to 1.15The analyzed GMT ratio, 95% confidence interval, and P-value were based on a longitudinal regression model adjusting for age and vaccination group
PrimaryGeometric Mean Fold Rise (GMFR) From Day 1 (Baseline) to Week 6 Postvaccination in VZV Antibody Titers

VZV antibody titers were determined by gpELISA. The GMFR measures the rise in VZV antibodies from Day 1 (Baseline) to Week 6 postvaccination.

Time frame:
Day 1 (Baseline) and Week 6 postvaccination
Reported as:
Geometric mean · Fold Rise
Geometric Mean Fold Rise (GMFR) From Day 1 (Baseline) to Week 6 Postvaccination in VZV Antibody Titers
Fold RiseGroup 1: Booster Dose Participants ≥70 Years of Age
Geometric Mean Fold Rise (GMFR) From Day 1 (Baseline) to Week 6 Postvaccination in VZV Antibody Titers1.5 (1.4 to 1.6)
Statistical analysis
  • Group 1: Booster Dose Participants ≥70 Years of Age · Longitudinal regression model · p = <0.001 (The alpha threshold for statistical significance is 0.025 (1-sided)) · Geometric mean fold rise: 1.54 · 95% CI 1.44 to 1.66The analyzed GMFR, 95% confidence interval, and P-value were based on a longitudinal regression model adjusting for age
SecondaryNumber of Participants Reporting One or More Adverse Experiences

An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience. A serious adverse experience is any AE that results in death, is life threatening, results in persistent disability/incapacity, results in or prolongs existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is another important medical event that may jeopardize the participant and may require medical or surgical intervention. Vaccine-related AEs were those assessed by the investigator as definitely, probably, or possibly related to vaccine administration. This outcome measure applies only to AEs collected after vaccination in Part 1 of the current study.

Time frame:
Up to 42 days postvaccination
Reported as:
Number · Participants
Number of Participants Reporting One or More Adverse Experiences
ParticipantsGroup 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of Age
Any Adverse Event104957272
Injection-site Adverse Event68615657
Non-Injection-site Adverse Event66573438
Serious Adverse Event3510
Vaccine-related Serious Adverse Event0000

Adverse events

Collected over Up to 42 days postvaccination: all AEs; Day 43 to Week 52: SAEs only; Week 156: SAEs only within 24 hours of the Week-156 blood draw (Groups 1 and 2 only). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Booster Dose Participants ≥70 Years of Age—29/201 (14.4%)76/201 (37.8%)
Group 2: First Dose Participants ≥70 Years of Age—29/199 (14.6%)58/199 (29.1%)
Group 3: First Dose Participants ≥60 and <70 Years of Age—6/100 (6%)61/100 (61%)
Group 4: First Dose Participants ≥50 and <60 Years of Age—2/100 (2%)62/100 (62%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventGroup 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of Age
SyncopeNervous system disorders1/2013/1990/1000/100
IleusGastrointestinal disorders0/2012/1990/1000/100
Atrial FibrillationCardiac disorders1/2012/1991/1000/100
Acute kidney injuryRenal and urinary disorders0/2012/1991/1000/100
Wound haemorrhageInjury, poisoning and procedural complications0/2010/1991/1000/100
Coronary artery diseaseCardiac disorders0/2010/1991/1000/100
Abdominal herniaGastrointestinal disorders0/2010/1991/1000/100
Large intestinal ulcer haemorrhageGastrointestinal disorders0/2010/1991/1000/100
RhinitisInfections and infestations0/2010/1991/1000/100
Procedural hypertensionInjury, poisoning and procedural complications0/2010/1991/1000/100
Most frequent other events
Most frequent other events
EventGroup 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of Age
Injection-site painGeneral disorders47/20128/19942/10048/100
Injection-site erythemaGeneral disorders44/20147/19941/10040/100
Injection-site swellingGeneral disorders31/20124/19929/10033/100
Injection-site pruritusGeneral disorders10/2019/1999/10011/100
HeadacheNervous system disorders8/2014/1993/1009/100
NasopharyngitisInfections and infestations11/2012/1995/1007/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of AgeTotal
Mean77.1 ± 4.576.3 ± 5.164.1 ± 3.155.5 ± 2.871.1 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Booster Dose Participants ≥70 Years of AgeGroup 2: First Dose Participants ≥70 Years of AgeGroup 3: First Dose Participants ≥60 and <70 Years of AgeGroup 4: First Dose Participants ≥50 and <60 Years of AgeTotal
Female107946577343
Male941053523257
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults. J Infect Dis. 2016 Jan 1;213(1):14-22. doi: 10.1093/infdis/jiv480. Epub 2015 Oct 9. PubMed 26452397 ↗
  • Weinberg A, Popmihajlov Z, Schmader KE, Johnson MJ, Caldas Y, Salazar AT, Canniff J, McCarson BJ, Martin J, Pang L, Levin MJ. Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine. J Infect Dis. 2019 Jan 7;219(2):335-338. doi: 10.1093/infdis/jiy514. PubMed 30165651 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Jul 2012 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2010
First posted
Nov 22, 2010
Start
Apr 2011
Primary completionActual
Jul 2012
CompletionActual
May 2015
Results first posted
May 29, 2013
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01245751
Responsible party
Sponsor
First posted
Nov 22, 2010
Start date
Apr 2011
Primary completion
Jul 2012
Completion
May 2015
Results posted
May 29, 2013
Last update
Apr 12, 2017

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion